Learn about optimizing treatment of multiple sclerosis (MS) using NEDA from Professor Frederic Barkhof, Professor Olga Ciccarelli and Dr. Jeremy Chataway of the University College London, UK.

Professor Frederik Barkhof, Professor Olga Ciccarelli and Dr. Jeremy Chataway of the University College London, UK, review the concept of no evidence of disease activity (NEDA) in multiple sclerosis and its potential clinical applications. In this highly interactive course Professor Barkhof and colleagues discuss the need for novel approaches to disease activity assessment in patients with relapse-remitting multiple sclerosis (RRMS) undergoing therapy with disease-modifying drugs, and review the evidence base supporting the efficacy of current/emerging therapies in achieving NEDA. Based on their own practical experience, the expert faculty review the latest publications in the field and discuss how novel measures of disease activity, such as NEDA-3 and NEDA-4, can be used in clinical studies to determine those therapies that may have the greatest potential to ameliorate disease progression and enhance patient outcomes.

This course has been awarded 1 European CME credit (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME). Developed by faculty to support physicians in understanding the concept of treating to a target of NEDA in multiple sclerosis and its potential clinical applications, this 1-hour course utilizes a blend of interactive formats and videos to facilitate and reinforce learning. The programme is supported by an independent educational grant from Merck KGaA. The supporter has had no involvement in the development of the scientific programme, content, or faculty selection; these are the responsibility of the Programme Director Professor Frederic Barkhof and the organizers International Medical Press.